Newly diagnosed NHL subjects had a higher EMAP II+CD4+% than patients with CR [median: 7.4% (range 6.8-8.1) vs. 2.3% (range 1.5-2.7); P = 0.001] as well as a higher percentage of EMAP II+CD8+ [median: 4% (range 4-5) vs. 0.6 (range 0.4-0.7); P = 0.001]. The gene discussed is AIMP1; the disease is non-Hodgkin lymphoma.